🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

ONS-5010

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.

Tags: biopharmaceutical, clinical trial, monoclonal antibodies, ophthalmic, retina diseases

Website

About | About | Leadership | Directors | About | Contact | Careers | Careers | Careers | Jobs | About | About

Symbol: OTLK

Recent Price: $1.86

Industry: Biotechnology

CEO: Mr. C. Russell Trenary III

Sector: Healthcare

Employees: 24

Address: Building F, Iselin, NJ 08852

Phone: 609 619 3990

Leadership

  • Randy Thurman, Executive Chairman
  • Yezan Haddadin, Member of the Board of Directors
  • Kurt J. Hilzinger, Member of the Board of Directors
  • Julia A. Haller, MD, Member of the Board of Directors
  • C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
  • Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
  • Faisal G. Sukhtian, Executive Director
  • Julian Gangolli, Member of the Board of Directors
  • Gerd Auffarth, MD, Member of the Board of Directors
  • Andong Huang, Vice President, Business Development

Last updated: 2024-12-31